Empowering or impeding return migration? ICT, mobile phones, and older migrants' communications with home

In the last two decades, transnational social fields have been transformed by advances in information and communication technologies (ICT). Many scholars have noted the empowering effects of these technological advances for migrants. Drawing on the concept of return preparedness, it follows that ICT use should also empower prospective returnees, enabling them to be better informed and prepared for return. However, multi‐sited ethnographic research with older North and West African men living in migrant worker hostels in France finds that ICT use – particularly mobile telephony –impedes return. In some instances, mobile phones serve to amplify the pressures on the men to provide financially for their stay‐at‐home relatives. In others, mobile phones reinforce attachments to France by facilitating networks of solidarity among hostel residents. Instead of returning definitively at retirement, many hostel residents choose a bi‐residence strategy, dividing their time between France and countries of origin

Scientific performance of ophthalmological research institutions in Germany 2018-2020. Studies, publications, third-party funding and more-The research map of the German Ophthalmological Society (DOG)

Background: The German Ophthalmological Society (DOG) regularly records the scientific activities of ophthalmological research institutions in Germany. Objective: With this publication the DOG wants to make the performance of scientific ophthalmology in Germany transparent and increase the options for future research cooperation with facilities of research institutions. Methods: Systematic survey of German research centers in ophthalmology. Results: The current research map records the data from 41 German research centers for the reporting period 2018-2020. Compared to previous editions of the research map, there has been a significant increase in scientific activity. The number of studies reported rose to 496. The number of government funded research projects (n = 121) and projects funded by foundations (n= 108) also increased. Furthermore, the number of scientific publications has almost doubled: while 1919 were published in the period from 2012 to 2014 and 2305 in the period from 2015 to 2017, there were 4215 in the current reporting period. The map also reports on a continuous increase in the number of young scientists in ophthalmology. Conclusion: The research map demonstrates the performance of German scientific ophthalmology. At the same time, the need for research in ophthalmology remains high because many diseases that affect the eyes are not yet or not yet completely curable

Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma

Background: The GLARIUS trial, which investigated the efficacy of bevacizumab (BEV)/irinotecan (IRI) compared with standard temozolomide in the first-line therapy of O-6-methylguanine-DNA methyltransferase (MGMT)nonmethylated glioblastoma, showed that progression-free survival was significantly prolonged by BEV/IRI, while overall survival was similar in both arms. The present report focuses on quality of life (QoL) and Karnofsky performance score (KPS) during the whole course of the disease. Methods: Patients (n = 170) received standard radiotherapy and were randomized (2: 1) for BEV/IRI or standard temozolomide. At least every 3 months KPS was determined and QoL was measured using the European Organisation for Research and Treatment of Cancer 30-item Core Quality of Life and 20-item Brain Neoplasm questionnaires. A generalized estimating equation (GEE) model evaluated differences in the course of QoL and KPS over time. Also, the time to first deterioration and the time to postprogression deterioration were analyzed separately. Results: In all dimensions of QoL and KPS, GEE analyses and time to first deterioration analyses did not detect significant differences between the treatment arms. At progression, 82% of patients receiving second-line therapy in the standard arm received BEV second-line therapy. For the dimensions of motor dysfunction and headaches, time to postprogression deterioration was prolonged in the standard arm receiving crossover second-line BEV in the vast majority of patients at the time of evaluation. Conclusions: GLARIUS did not find indications for a BEV-induced detrimental effect on QoL in first-line therapy of MGMT-nonmethylated GBM patients. Moreover, GLARIUS provided some indirect corroborative data supporting the notion that BEV may have beneficial effects upon QoL in relapsed GBM